Showing chemical card for HZT-501 (CFc000323648)
| Record Information | |
|---|---|
| Version | 1.0 |
| Creation Date | 2022-09-06 19:45:53 UTC |
| Update Date | 2022-09-14 04:54:45 UTC |
| Chemfont ID | CFc000323648 |
| Molecule Identification | |
| Common Name | HZT-501 |
| Definition | HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. |
| Structure |  |
| Synonyms | Not Available |
| Chemical Formula | |
| Average Molecular Weight | |
| Monoisotopic Molecular Weight | |
| IUPAC Name | |
| Traditional Name | |
| CAS Registry Number | Not Available |
| SMILES | Not Available |
| InChI Identifier | |
| InChI Key | |
| Chemical Taxonomy | |
| Classification | Not classified |
| Functional Ontology | |
| Physiological effect | Not Available |
| Disposition | |
| Process | Not Available |
| Role | Not Available |
| Physical Properties | |
| Predicted Properties | Not Available |
| External Links | |
| External Links | Not Available |
| References | |
| Synthesis Reference | Not Available |